Main Products:
(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol,
Saxagliptin,
Lurasidone,
Introduct:
Nanjing Wellcare Bio-Pharmaceutical Co., Ltd. was established in August 2010, located at No. 15 Wanshou Road, Nanjing Pukou Economic Development Zone, within the Nanjing Tech University Science and Technology Industrial Park. It is a high-tech biopharmaceutical enterprise founded and managed by an overseas returnee entrepreneurial team. In April 2015, it joined China's top 500 enterprise—Jilin Yatai (Group) Co., Ltd. (Stock Code: 600881).
The company focuses on innovative drug research and development, generic drug technology transfer, and the production and sales of pharmaceutical intermediates. It possesses a comprehensive R&D, production, and sales system, well-equipped synthesis, formulation, and drug analysis laboratories, and has established industrial partnership relationships with multiple manufacturers, laying a solid foundation for the industrialization and marketization of Wellcare's projects. The company has completed the independent and collaborative development of more than ten high-end generic drugs, with product lines primarily concentrated in the fields of cardiovascular and cerebrovascular diseases, mental disorders, and endocrine diseases. The entire product line has formed an R&D梯队, with many products being domestically exclusive or leading.
After four years of development and an investment of over ten million yuan, the company's anti-thrombosis new drug "Vicagrel," developed in collaboration with China Pharmaceutical University, received clinical approval in March 2015. Governments at all levels have attached great importance to and supported this innovative project. The company has received multiple fund supports, including the "Nanjing Science and Technology SME Innovation Fund Project," "Pukou District Science and Technology Development Plan," "Jiangsu Province Science and Technology SME Technological Innovation Fund Project," "Ministry of Science and Technology Science and Technology SME Technological Innovation Fund," and the "Twelfth Five-Year Plan" major special project (rolling).
Since its establishment, the company has experienced rapid growth, employing over 200 people, including 8 PhDs and nearly 70 master's degree holders. The company has applied for a total of 56 domestic and international invention patents (including 16 authorized patents in the United States, Japan, and the EU), with 4 PCT patent applications. It has successively received support from more than 20 national, provincial, and municipal government funds and special funds. The company has been awarded 16 government funds at various levels. In 2011, the company was rated as a "Jiangsu Province Private Science and Technology Enterprise." In 2013, it obtained the titles of "High-Tech Enterprise" and "Jiangsu Province Science and Technology SME." In 2016, the company was recognized as the Nanjing Chemical Synthetic Drug Engineering Technology Research Center. In 2012, the company participated in the first China Innovation and Entrepreneurship Competition and won the "Outstanding Enterprise" award in the division. In 2013, it participated in the first Jiangsu Innovation and Entrepreneurship Competition and won the second prize in the province.
We adopt "The better Care, The better Medicines" as our corporate philosophy. In the course of our operations, we emphasize attention and care for our employees, our partners, our product quality, and clinical needs, enabling employees to fully utilize their autonomy and creativity, working and living happily. The company grows together with its partners, developing products that meet clinical needs with the best quality, creating better economic and social benefits. We strive to achieve domestic advanced levels in comprehensive chemical drug R&D capabilities within the next ten years.,
